The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...
TOKYO--(BUSINESS WIRE)--Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer ...
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis. Investigators in South Korea demonstrated the benefit in a ...
TOKYO--(BUSINESS WIRE)--A novel and relatively pain-less treatment method for male urethral stricture using patients own buccal mucosal cells has been reported as successful in four out of six ...
A team of surgeons in the University College Hospital (UCH), Ibadan, led by Prof. Olayinka Shittu, has successfully performed an intricate procedure to reconstruct a urethral stricture in a ...
STRICTURES of the human urethra are of three types: inflammatory, traumatic and congenital. The basic histology 1 common to all strictures is a proliferation of fibroblasts in the tunica propria. This ...
Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to patients ...
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback